The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
New inhalers would have near-zero Global Warming Potential propellant
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
